MedPath

18F-PSMA-1007 PET/CT in primary staging of prostate cancer

Conditions
intermediate-high risk prostate cancer, primary staging, diagnostics
Registration Number
NL-OMON24419
Lead Sponsor
Canisius Wilhelmina ZiekenhuisWeg door Jonkerbos 1006532 SZ NijmegenThe Netherlands
Brief Summary

ot applicable

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Not specified
Target Recruitment
100
Inclusion Criteria

1.Biopsy proven adenocarcinoma of the prostate;

2.Indication for (super)extended pelvic lymph node dissection (PLND - with or without robot-assisted laparoscopic prostatectomy);

Exclusion Criteria

1.History of prior diagnosed or treated PCa.

2.Known concomitant malignancies (except Basal Cell Carcinoma of the skin).

Study & Design

Study Type
Observational non invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Diagnostic accuracy (sensitivity, specificity, PPV and NPV) of 18F-PSMA-1007 PET/CT for the detection of (regional) lymph node metastases in the initial staging of intermediate-to high risk PCa patients.
Secondary Outcome Measures
NameTimeMethod
a. Diagnostic accuracy (specificity, PPV) of 18F-PSMA-1007 PET/CT for the detection of distant (bone) metastases.<br /><br>b. Diagnostic accuracy of 18F-PSMA-1007 PET/CT in staging of the primary tumor in the<br>radical prostatectomy specimen.<br /><br>c. Diagnostic accuracy of 18F-PSMA-1007 PET/CT for different risk groups (according to the d¡¯Amico classification ¨C see chapter 5.1.3), nomogram risk scores, and the size of malignant lymph nodes.<br /><br>d. Diagnostic performance of 18F-PSMA-1007 PET/CT versus conventional imaging (skeletal scintigraphy, MRI of the prostate) in detection of local tumor site and metastases.<br /><br>e. Change of management induced by 18F-PSMA-1007 PET/CT findings specifically.<br /><br>f. Cost-effectiveness of 18F-PSMA-1007 PET/CT versus (super)extended PLND (e.g. mean hospital length of stay, morbidity-associated costs) for the detection of (regional)<br>LNMs.<br>
© Copyright 2025. All Rights Reserved by MedPath